Genomic Landscape of Murine Metabolic-dysfunction Associated Steatohepatitis (MASH): Unveiling Key Molecular Signatures through Meta-Analysis and Fisher's …
V Andrade, Y Shu - 2024 - archive.hshsl.umaryland.edu
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) presents as a
complex and multifactorial liver disorder characterized by inflammation, hepatocyte injury …
complex and multifactorial liver disorder characterized by inflammation, hepatocyte injury …
Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression
IS Piras, JK DiStefano - Life Science Alliance, 2024 - life-science-alliance.org
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form,
metabolic dysfunction-associated steatohepatitis (MASH), pose significant risks of severe …
metabolic dysfunction-associated steatohepatitis (MASH), pose significant risks of severe …
[HTML][HTML] The gene expression signature of metabolic dysfunction-associated steatotic liver disease from a multiomics perspective
CJ Pirola, S Sookoian - Clinical and Molecular Hepatology, 2024 - ncbi.nlm.nih.gov
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe clinical
form, metabolic dysfunctionassociated steatohepatitis (MASH), are chronic liver diseases …
form, metabolic dysfunctionassociated steatohepatitis (MASH), are chronic liver diseases …
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
S Wang, SL Friedman - Science translational medicine, 2023 - science.org
Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …
that poses a global health threat because of its potential to progress to advanced fibrosis …
Development of a multi-species scRNA-seq atlas of metabolic dysfunction–sssociated steatotic liver disease (MASLD)
M Demirdizen - repository.bilkent.edu.tr
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a significant
portion of the human population, potentially leading to severe secondary conditions. Despite …
portion of the human population, potentially leading to severe secondary conditions. Despite …
MegaMASLD: An interactive platform for exploring stratified transcriptomic signatures in MASLD progression
HS Cheng, D Chua, ST Chan, KC Yew, HS Wong… - bioRxiv, 2024 - biorxiv.org
Liver transcriptomic data from patients with metabolic dysfunction-associated steatotic liver
disease (MASLD) offers valuable resource for deciphering pathogenic molecular drivers …
disease (MASLD) offers valuable resource for deciphering pathogenic molecular drivers …
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
TJ Kendall, M Jimenez-Ramos, F Turner… - Nature medicine, 2023 - nature.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause
of chronic liver disease worldwide and represents an unmet precision medicine challenge …
of chronic liver disease worldwide and represents an unmet precision medicine challenge …
Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human
S Tsouka, P Kumar, P Seubnooch… - Communications …, 2024 - nature.com
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent
chronic liver disease worldwide, and can rapidly progress to metabolic dysfunction …
chronic liver disease worldwide, and can rapidly progress to metabolic dysfunction …
[HTML][HTML] Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets
METHODS: We analysed 2,941 plasma proteins in 43,978 European participants from UK
Biobank. We performed genome-wide association study (GWAS) for all MASLD-associated …
Biobank. We performed genome-wide association study (GWAS) for all MASLD-associated …
Integrated computational-experimental approach to identify and optimise drug therapy for metabolic dysfunction-associated steatotic liver disease
M Jimenez Ramos - 2024 - era.ed.ac.uk
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common
chronic liver disease worldwide, affecting more than one in four people, and is the leading …
chronic liver disease worldwide, affecting more than one in four people, and is the leading …
相关搜索
- rna seq meta analysis
- associated steatohepatitis meta analysis
- probability test meta analysis
- rna seq probability test
- rna seq associated steatohepatitis
- associated steatohepatitis probability test
- associated steatohepatitis genomic landscape
- genomic landscape meta analysis
- associated steatohepatitis metabolic dysfunction
- rna seq genomic landscape
- genomic landscape probability test
- masld progression meta analysis
- spatial genomics liver disease
- multiomics perspective liver disease
- genome and proteome liver disease
- multimodal database liver disease